Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | P4HB | P07237 | 2/20 | 0.33 |
| ▸ | S100A9 | P06702 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7990621 | 0.79 | MAOB (0.51) | EGLN1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7993915 | 0.75 | ALKBH1 (0.38) | EGLN1ALKBH1GAA | |
| SCHEMBL7990262 | 0.75 | ALKBH1 (0.40) | ALKBH1GAA | |
| SCHEMBL15694306 | 0.68 | HSD11B1 (0.37) | — | |
| SCHEMBL7031067 | 0.66 | LMNA (0.52) | ALKBH1CYP19A1 | |
| SCHEMBL23247291 | 0.64 | HPGDS (0.60) | HPGDSSYKGABRG2GABRB3GABRA3 | |
| SCHEMBL26603007 | 0.64 | CYP11B1 (0.40) | HPGDSGABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL19212182 | 0.63 | HPGDS (0.45) | HPGDSGAAEGLN2 | |
| SCHEMBL31087475 | 0.63 | HPGDS (0.45) | HPGDSGAAEGLN2 | |
| SCHEMBL29108720 | 0.63 | MPO (0.37) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |